$5 million financing completed by Paragon Bioservices to fuel Expansion

$5 million financing completed by Paragon Bioservices to fuel Expansion
<span>A $5 million unregistered equity financing by&nbsp;<font><a href="http://www.paragonbioservices.com/" target="_blank">Paragon Bioservices</a></font>&nbsp;successfully drew to a close. The non-brokered investment round was placed among nine investors. The subscription started a few days ago. The company closed three previous unregistered private placements which raised an estimated $19.9 million.</span>
XDATA - August 6th 2018
A $5 million unregistered equity financing by Paragon Bioservices successfully drew to a close. The non-brokered investment round was placed among nine investors. The subscription started a few days ago. The company closed three previous unregistered private placements which raised an estimated $19.9 million.
The company is a contract research and manufacturing organization with a focus on biopharmaceuticals including the production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. Investors include NewSpring Capital and Camden Partners.
The company, headquartered in Baltimore MD, is led by Peter Buzy (CEO and President). Paragon Bioservices elected to keep its revenues undisclosed.
The board of directors includes Donald Hughes, Kapila Ratnam, Marco Chacon, Patrick Hervy and Robert Roche.

The company has raised an estimated total of $24.9 million via private unregistered security offerings.
Offering recap
Status: Completed
Company: Paragon Bioservices
Industry: Biotechnology
Amount offered: $5 million
Amount placed: $5 million
SEC filing: Source 
First sale: 08-03-2018
Data as of: 08-06-2018
Source: www.marketdataconnect.com